Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 11/2016

01-11-2016 | Review Article

Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura

Author: Ahmet Emre Eskazan

Published in: Annals of Hematology | Issue 11/2016

Login to get access

Abstract

Therapeutic plasma exchange (TPE) has dramatically improved the prognosis of acquired thrombotic thrombocytopenic purpura (TTP), and TPE and corticosteroids are the mainstays of treatment of acquired TTP. However, a subset of patients may remain refractory to this treatment modality, or have an initial response but relapse after the discontinuation of TPE during the follow-up. While managing patients with relapsed/refractory acquired TTP, there are several therapeutic maneuvers, which can be considered. Recently, there came some papers regarding the use of bortezomib in relapsed or refractory acquired TTP, and in this review, this indication of bortezomib was evaluated along with the current data available. In seven published papers, 12 patients with relapsed/refractory acquired TTP received bortezomib, of which 11 survived the acute episodes and maintained remission. Bortezomib may serve as an adjunct treatment, but prospective trials are needed to determine the dosing, administration route, and the treatment schedule of this treatment option in patients with relapsed/refractory TTP.
Literature
1.
Eskazan AE, Salihoglu A (2015) Treatment and outcome of primary and secondary thrombotic microangiopathies. Am J Nephrol 41(6):427–428CrossRefPubMed
2.
3.
4.
Shortt J, Oh DH, Opat SS (2013) ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 368(1):90–92CrossRefPubMed
5.
Yates S, Matevosyan K, Rutherford C et al (2014) Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion 54(8):2064–2067CrossRefPubMed
6.
Mazepa MA, Raval JS, Moll S et al (2014) Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 164(6):900–902CrossRefPubMed
7.
van Balen T, Schreuder MF, de Jong H et al (2014) Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib. Eur J Haematol 92(1):80–82CrossRefPubMed
8.
Patel PP, Becker J, Freyer C et al (2016) Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib. Transfusion. doi:10.​1111/​trf.​13465
9.
10.
11.
Nguyen L, Li X, Duvall D et al (2008) Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion 48(2):349–357PubMed
12.
Bell WR, Braine HG, Ness PM et al (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 325(6):398–403CrossRefPubMed
13.
Balduini CL, Gugliotta L, Luppi M et al (2010) Italian TTP Study Group. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol 89(6):591–596CrossRefPubMed
14.
Lim W, Vesely SK, George JN (2015) The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood 125(10):1526–1531CrossRefPubMedPubMedCentral
15.
Ongoren Aydin S, Sadri S, Apaydin T et al (2014) The efficacy of vincristine in the treatment of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Haematologica 99(s1):474 [abstract]
16.
Beloncle F, Buffet M, Coindre J-P et al (2012) Thrombotic microangiopathies reference center. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA reference center experience. Transfusion 52(11):2436–2444CrossRefPubMed
17.
Yilmaz M, Eskazan AE, Unsal A et al (2013) Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature. Transfusion 53(7):1586–1593CrossRefPubMed
18.
Kappers-Klunne MC, Wijermans P, Fijnheer R et al (2005) Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 130(5):768–776CrossRefPubMed
19.
Kouroukis CT, Baldassarre FG, Haynes AE et al (2014) Cancer Care Ontario Hematology Disease Site Group. Bortezomib in multiple myeloma: a practice guideline. Clin Oncol (R Coll Radiol) 26(2):110–119CrossRef
20.
21.
Vincent RS (2014) Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89(10):999–1009
22.
23.
Shah N, Meouchy J, Qazi Y (2015) Bortezomib in kidney transplantation. Curr Opin Organ Transplant 20(6):652–656PubMed
24.
Paterno F, Shiller M, Tillery G et al (2012) Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 12(9):2526–2531CrossRefPubMedPubMedCentral
25.
Mateos MV (2010) Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 36(Suppl 2):S24–S32CrossRefPubMed
26.
Mateos MV, San Miguel JF (2012) Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol 3(2):117–124CrossRefPubMedPubMedCentral
27.
Zakarija A, Bennett C (2005) Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 31(6):681–690CrossRefPubMed
28.
Morita R, Hashino S, Shirai S et al (2008) Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol 88(2):248–250CrossRefPubMed
29.
Mehta N, Saxena A, Niesvizky R (2012) Bortezomib-induced thrombotic thrombocytopaenic purpura. BMJ Case Rep vol.2012
30.
Moore H, Romeril K (2011) Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Intern Med J 41(4):348–350CrossRefPubMed
31.
Salmenniemi U, Remes K (2012) Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep 4(2):e13PubMedPubMedCentral
32.
33.
Honton B, Despas F, Dumonteil N et al (2014) Bortezomib and heart failure: case-report and review of the French pharmacovigilance database. Fundam Clin Pharmacol 28(3):349–352CrossRefPubMed
34.
Park SJ, Cheong HI, Shin JI (2013) Antibody depletion by bortezomib through blocking of antigen presentation. N Engl J Med 368(14):1364–1365CrossRefPubMed
35.
Subklewe M, Sebelin-Wulf K, Beier C et al (2007) Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol 68(3):147–155CrossRefPubMed
36.
Bhagirath VC, Kelton JG, Moore J et al (2012) Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura. Transfusion 52(12):2517–2523CrossRefPubMed
37.
Hie M, Gay J, Galicier L et al (2014) French Thrombotic Microangiopathies Reference Centre. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 124(2):204–210CrossRefPubMed
38.
Sonneveld P, Schmidt-Wolf IG, van der Holt B et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 30(24):2946–2955CrossRefPubMed
Metadata
Title
Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura
Author
Ahmet Emre Eskazan
Publication date
01-11-2016
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 11/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2804-x

Other articles of this Issue 11/2016

Annals of Hematology 11/2016 Go to the issue

Original Article

Evaluation of neutrophil–lymphocyte ratio in patients with early-stage mycosis fungoides

Letter to the Editor

Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia

Letter to the Editor

Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety

Original Article

Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia

Letter to the Editor

Carfilzomib: a rare cause of posterior reversible encephalopathy syndrome

Review Article

Bone marrow niche in immune thrombocytopenia: a focus on megakaryopoiesis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits